查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2068579

持續性角膜上皮缺損（PCED）：新型療法、未滿足的需求與TPP洞察報告，2026年

Persistent Corneal Epithelial Defect (PCED) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 德國持續性角膜上皮缺損市場預計將從 2025 年的 2,384 萬美元成長到 2035 年的 2.1,289 億美元，顯示市場擴張強勁。
  • 以下因素正在推動市場成長：
  • 難治性和復發性病例的診斷數量增加
  • 擴大先進生物製藥和再生醫學在眼科治療的應用。
  • 改善獲得專業眼科護理和罕見疾病管理的機會
  • 市場規模得益於創新療法的高價定價，以及對能夠促進角膜癒合和預防復發的療法日益成長的需求。
  • 針對角膜再生、神經癒合和上皮修復的新療法有望在德國創造巨大的商業性機會。
  • 未來的成長取決於先進生物製藥和治療方法的成功引入，這些製劑和治療方法可以降低復發率，同時改善長期視力預後。

針對持續性角膜上皮缺損 (PCED) 和 TPP 的新療法

Thelansis 的「持續性角膜上皮缺損 (PCED)：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026」對該適應症的關鍵新興療法和主要藥物開發機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。

持續性角膜上皮缺損（PCED）概述

持續性角膜上皮缺損（PCED）是嚴重的眼科疾病可能導致角膜基質溶解、穿孔和永久性瘢痕形成。診斷方法包括裂隙燈顯微鏡檢查（螢光素染色）、角膜感覺追蹤檢查和前節OCT檢查。基礎治療包括使用不含防腐劑的潤滑劑、治療性繃帶式隱形眼鏡以及低劑量口服多西環素以抑制分解組織的基質金屬蛋白酶。生物修復方法包括自體或異體血清眼藥水，但重組神經生長因子塞尼格明是目前核准的第一線標準治療藥物，特別適用於神經營養性缺損。到2026年，目標是透過非神經營養途徑，利用Lufepilsen滴眼液和Secretome滴眼液等研發療法，實現機械和細胞修復。羊膜移植和眼瞼縫合術將僅限於需要積極治療的難治性病例。

主要亮點

  • 在德國，復發性和難治性持續性角膜上皮缺損（PCED）病例數預計將從 2025 年的 718 例增加到 2035 年的 827 例，反映出該疾病負擔的逐漸增加。
  • 持續性角膜上皮缺損是一種嚴重的眼表疾病，與角膜癒合受損、視力喪失風險以及疾病復發進展有關。
  • 人們意識的提高、眼科診斷技術的進步以及神經營養性角膜炎和糖尿病等潛在疾病盛行率的上升，都促進了診斷率的提高。
  • 對於復發或難治性疾病患者而言，傳統潤滑劑、繃帶式隱形眼鏡和輔助療法均無法充分滿足其治療需求，因此仍存在著巨大的未滿足需求。
  • 隨著人們對生物製藥、再生醫學和新型眼科製劑的關注度不斷提高，預計在預測期內，治療格局將發生巨大變化。
  • 受生物製藥普及和人們對罕見角膜疾病的認知不斷提高的推動，預計到 2030 年，全球神經營養性角膜炎治療市場將以約 9% 的複合年成長率成長。

基於對醫生和關鍵意見領袖（KOL）的調查得出的結論：

  • 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興療法條件的患者
  • 大公司
  • 主要作用機制
  • 發布日期預測等。
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機遇
  • 目前主要療法的有效性
  • 未滿足需求的關鍵領域
  • 主要未滿足需求的市場規模估算
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵意見領袖對領先新興療法的見解
  • 意識
  • 預期用途/處理線
  • 主要未滿足需求得到滿足的程度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Dompe Farmaceutici SpA
  • Glaukos Corporation

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要療法概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章：初步調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興療法
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

  • 新興療法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

簡介目錄

Persistent Corneal Epithelial Defect (PCED) Emerging Therapy and TPP Insights

Thelansis's "Persistent Corneal Epithelial Defect (PCED) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Persistent Corneal Epithelial Defect (PCED) Overview

Persistent corneal epithelial defect (PCED) is a severe ocular pathology defined by the failure of the corneal epithelium to close within two weeks despite standard management. Resulting from a disrupted regenerative cycle, it stems from neurotrophic keratopathy, limbal stem cell deficiency, chemical burns, or severe ocular surface disease. Left untreated, chronic defects risk stromal melting, perforation, and permanent scarring. Diagnosis relies on slit-lamp biomicroscopy with fluorescein staining, corneal sensitivity tracking, and anterior segment OCT. Foundational management utilizes preservative-free lubrication, therapeutic bandage contact lenses, and low-dose oral doxycycline to inhibit tissue-degrading matrix metalloproteinases. Biologic repair utilizes autologous or allogeneic serum drops, while the recombinant nerve growth factor cenegermin serves as the approved frontline standard specifically for neurotrophic defects. In 2026, non-neurotrophic pathways target mechanical and cellular restoration via pipeline options like lufepirsen ophthalmic gel or secretome drops. Amniotic membrane transplantation or tarsorrhaphy is reserved for refractory cases requiring aggressive closure.

Key Highlights

  • In Germany, relapse and refractory Persistent Corneal Epithelial Defect (PCED) cases are projected to increase from 718 patients in 2025 to 827 patients by 2035, reflecting a gradual rise in disease burden.
  • Persistent Corneal Epithelial Defect remains a serious ocular surface condition associated with impaired corneal healing, vision loss risk, and recurrent disease progression.
  • Increasing awareness, improved ophthalmic diagnostics, and rising prevalence of underlying conditions such as neurotrophic keratitis and diabetes are contributing to higher diagnosis rates.
  • Significant unmet need persists in relapse and refractory patients who demonstrate inadequate response to conventional lubricants, bandage contact lenses, and supportive therapies.
  • Growing focus on biologics, regenerative therapies, and novel ophthalmic formulations is expected to transform the treatment landscape over the forecast period.
  • The global neurotrophic keratitis treatment market is projected to grow at nearly 9% CAGR through 2030, supported by increasing biologic adoption and expanding recognition of rare corneal disorders.

Market Overview

  • The Germany Persistent Corneal Epithelial Defect market is projected to grow from USD 23.84 million in 2025 to USD 212.89 million by 2035, indicating strong market expansion.
  • Market growth is driven by:
  • Increasing diagnosis of refractory and relapse cases
  • Rising adoption of advanced biologics and regenerative ophthalmic therapies
  • Improved access to specialty eye care and rare disease management
  • Market value is supported by premium pricing of innovative therapies and growing demand for treatments capable of accelerating corneal healing and preventing recurrence.
  • Emerging therapies targeting corneal regeneration, nerve healing, and epithelial repair are expected to create substantial commercial opportunities in Germany.
  • Future growth will depend on the successful adoption of advanced biologics and therapies capable of improving long-term visual outcomes while reducing recurrence rates.

Insights driven by surveys with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Dompe Farmaceutici S.p.A.
  • Glaukos Corporation

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)